Skip to main content
. 2020 Jul 1;12(7):1754. doi: 10.3390/cancers12071754

Figure 1.

Figure 1

Overall survival rates for patients with metastatic PDAC according to RAS mutation status. (A) OS according to RAS mutation status in cfDNA; (B) OS according to RAS mutation status in tissue; (C) OS according to RAS mutation status in cfDNA of those patients with RAS mutations analyzed in tissue.